These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 8267981

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
    Lillehammer T, Tveito S, Engesaeter BO, Fodstad O, Maelandsmo GM, Engebraaten O.
    Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells.
    Shi CX, Long MA, Liu L, Graham FL, Gauldie J, Hitt MM.
    Mol Ther; 2004 Oct; 10(4):758-67. PubMed ID: 15451460
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models.
    Ko SC, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA, Karsenty G, Chung LW.
    Cancer Res; 1996 Oct 15; 56(20):4614-9. PubMed ID: 8840973
    [Abstract] [Full Text] [Related]

  • 28. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake.
    Egami T, Ohuchida K, Mizumoto K, Onimaru M, Toma H, Nishio S, Nagai E, Matsumoto K, Nakamura T, Tanaka M.
    Clin Cancer Res; 2008 Mar 15; 14(6):1859-67. PubMed ID: 18347189
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy.
    Scott SD, Joiner MC, Marples B.
    Gene Ther; 2002 Oct 15; 9(20):1396-402. PubMed ID: 12365005
    [Abstract] [Full Text] [Related]

  • 31. Human polyomavirus JCV late leader peptide region contains important regulatory elements.
    Akan I, Sariyer IK, Biffi R, Palermo V, Woolridge S, White MK, Amini S, Khalili K, Safak M.
    Virology; 2006 May 25; 349(1):66-78. PubMed ID: 16497349
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Transient promoter activity in primary rat mammary epithelial cells evaluated using particle bombardment gene transfer.
    Thompson TA, Gould MN, Burkholder JK, Yang NS.
    In Vitro Cell Dev Biol; 1993 Feb 25; 29A(2):165-70. PubMed ID: 8386156
    [Abstract] [Full Text] [Related]

  • 38. Construction of portable intron cassettes for the delivery and expression of foreign genes.
    Reilly JD, Silva RF.
    DNA Cell Biol; 1996 Dec 25; 15(12):1113-20. PubMed ID: 8985125
    [Abstract] [Full Text] [Related]

  • 39. Identification of the components necessary for adenovirus translational control and their utilization in cDNA expression vectors.
    Kaufman RJ.
    Proc Natl Acad Sci U S A; 1985 Feb 25; 82(3):689-93. PubMed ID: 2983309
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.